We have shown that proteasomal inhibition activated IRE1α to recruit TRAF2 and activate NF‐κB to transcribe inflammatory cytokine and chemokine, thus creating a favorable tumor microenvironment for immunotherapy. This evidence concerns the gene NFKB1 and neoplasm.